ENDO INTERNATIONAL PLC

(ENDP)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
0.4650 USD   -19.52%
05/09BMO Capital Lowers Price Target for Endo International to $2 From $4, Maintains Market Perform Rating
MT
05/09Barclays Trims Endo International's Price Target to $1 From $2, Maintains Underweight Rating
MT
05/06Piper Sandler Downgrades Endo International to Underweight From Neutral, Lowers PT to $1 From $3
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo International : at J.P. Morgan Healthcare Conference

01/11/2022 | 09:08am EDT

J.P. Morgan Healthcare Conference

Blaise Coleman, President & CEO

endo.com

©2022 Endo International plc or one of its affiliates. All rights reserved

Forward Looking Statements

This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1 995 and Canadian securities legislation. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forw ard," "intend," "guidance," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this presentation reflect Endo's current expectations of future events based on existing trends and information and represent Endo's judgment only as of the date of this presentation. Actual results may differ materially and adversely from current expectations based on a number of factors affecting Endo's businesses, including, among other things, the following: the outcome of our strategic review, conti ngency planning and any potential restructuring; the timing, impact or results of any pending or future litigation, investigations, claims or actual or contingent liabilities, settlement discussions, negotiations or other adverse proceedings; our

ability to satisfy judgments or settlements or pursue appeals including bonding requirements; our ability to adjust to changi ng market conditions; our ability to attract and retain key

personnel; our inability to maintain compliance with financial covenants and operating obligations which would expose us to p otential events of default under our outstanding indebtedness; our ability to incur additional debt or equity financing for working capital, capital expenditures, business de velopment, debt service requirements, acquisitions or general corporate or other purposes; our ability to refinance our indebtedness; a significant reduction in our short -term or long-term revenues which could cause us to be unable to fund our operations and liquidity needs or repay indebtedness. The occurrence or possibility of any such result has caused us to engag e, and may result in further engagement in strategic reviews that ultimately may result in our pursuing one or more significant corporate transactions or other remedial measures, including on a preventative or proactive basis. Those remedial measures could include a potential corporate reorganization, restructuring or bankruptcy filing involving all or a p ortion of our business, asset sales or other divestitures, cost-saving initiatives, corporate realignments or strategic partnerships. Some of these measures could take significant time to implement and others may require judicial or other third-party approval. Any such actions may be complex, could entail significant costs and charges or could otherwise negatively impact shareholder value, and there can be no assurance that we will be able to accomplish any of these alternatives on terms acceptable to us, or at all, or that they wil l result in their intended benefits. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law. Additional information concerning risk factors, including those referenced above, can be found in press releases issu ed by Endo, as well as Endo's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the head ing "Risk Factors" in Endo's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission.

2

©2022 Endo International plc or one of its affiliates. All rights reserved

Endo: A Diversified Specialty Pharmaceutical Company

Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate team members collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them.

Our Vision

Helping everyone we serve live their best life.

Our Mission

We develop and deliver life-enhancing products through focused execution.

Our Businesses

Branded Pharmaceuticals

Medical

Medical

Sterile

Generic

Therapeutics

Aesthetics

Injectables

Pharmaceuticals

3

©2022 Endo International plc or one of its affiliates. All rights reserved

Our Strategic Priorities

Expand &

Enhance Our

Portfolio

We are investing to build a more differentiated and durable portfolio that

benefits our customers and creates sustainable long- term value.

Reinvent How We Work

We are embracing the future by accelerating new ways of working to

better serve our customers, promote innovation, and improve productivity.

Be A Force

For Good

We are committed to the adoption of more sustainable practices

that positively impact our stakeholders, including the promotion of diversity & inclusion in all we do.

4

©2022 Endo International plc or one of its affiliates. All rights reserved

Our Branded Business Today

Medical Therapeutics + Medical Aesthetics

2021 Q3 YTD Revenue

Medical Therapeutics

Specialty products portfolio revenue CAGR of 14%;

XIAFLEX® CAGR of 19% 2017-2021E2

Broad portfolio of branded specialty products with

urology and orthopedics focus

Blazing new trails for non-surgical interventions

30%1

Medical Aesthetics

Launched 1st commercial product QWO for cellulite in Q1'21

Emerging non-surgical body contouring market has grown

nearly 500% in the last 5 years

Creating new category to tap into this opportunity

Credentialed medical aesthetics sales & marketing team

Scalable commercial infrastructure to support aesthetics

1 Represents percentage sales of overall reported sales

product portfolio

2 2021E amounts derived using revenue mid-points consistent with guidance provided on 11/4/2021

5

©2022 Endo International plc or one of its affiliates. All rights reserved

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Endo International plc published this content on 11 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2022 14:07:04 UTC.


© Publicnow 2022
All news about ENDO INTERNATIONAL PLC
05/09BMO Capital Lowers Price Target for Endo International to $2 From $4, Maintains Market ..
MT
05/09Barclays Trims Endo International's Price Target to $1 From $2, Maintains Underweight R..
MT
05/06Piper Sandler Downgrades Endo International to Underweight From Neutral, Lowers PT to $..
MT
05/06Top Midday Decliners
MT
05/06Endo International Posts Lower Q1 Adjusted Earnings, Revenue; Issues Q2 Guidance; Share..
MT
05/06ENDO INTERNATIONAL PLC Management's Discussion and Analysis of Financial Condition and..
AQ
05/06Tranche Update on Endo International plc's Equity Buyback Plan announced on April 30, 2..
CI
05/06Wall Street Set for Downbeat Session; US Jobs Report Shows Strong Gain
MT
05/06Top Premarket Decliners
MT
05/06TRANSCRIPT : Endo International plc, Q1 2022 Earnings Call, May 06, 2022
CI
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2022 2 321 M - -
Net income 2022 -269 M - -
Net Debt 2022 7 378 M - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 109 M 109 M -
EV / Sales 2022 3,23x
EV / Sales 2023 3,53x
Nbr of Employees 3 103
Free-Float 99,1%
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 5
Last Close Price 0,47 $
Average target price 1,33 $
Spread / Average Target 187%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
James Patrick Tursi Executive VP-Global Research & Development